الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 32 |  |  |
| | | from | 32 | | |
Abstract
SVR rate for treatment of HCV-4 using the standard of care
ranges from less than 50% to over 60%. It is important to optimize
the dose and duration of currently available treatment modalities,
namely PEG-IFN and RBV, for treatment of CHC.
Recent studies on early viral kinetics in HCV infected patients
show that almost 90% of patients treated with peg-IFN a-2b and
ribavirin experienced an end of the week rebound consistent with a
decline in serum IFN levels.
This clinical trial was conducted to study whether splitting the dose
of pegylated interferon a-2b affect the virological response.
Thirty naive HCV patients attending the outpatient clinic of
hepatology department, these patients were divided based on dose of
pegylated interferon into:
Group I: Patients received pegylated interferon a2b 1.5 y glkg
weekly plus ribavirin on weight-based regimen 1000 mg daily dose for
patient weight <75 kg and 1200 mg daily dose for patient (weight >75
kg). For 3 months.
Group 11: Patients received pegylated interferon a2b 0.75yglkg
twice weekly plus ribavirin on weight-based regimen for 3 months.
Summary and conclusion
All patients achieved EVR in both groups continue their regimen
of therapy as the standard regimen. Virological response was assessed
in both groups.
All virological response rates (RVR, EVR, ETR, and SVR), were
comparable in both groups. Side effects occurrences were similar in both
studied groups.
Factors associated with virological response in this study were low
GGT, hepatic fibrosis and lower HCV RNA. In addition, the study
showed that Hepatitis C patients who develop anemia during
treatment with pegylated interferon plus ribavirin and decline of
decline of hemoglobin more than 3 gm are more likely to achieve a
sustained virological response SVR.